Sivia Capital Partners LLC Grows Stock Position in Boston Scientific Co. (NYSE:BSX)

Sivia Capital Partners LLC lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 4.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,825 shares of the medical equipment provider’s stock after acquiring an additional 151 shares during the period. Sivia Capital Partners LLC’s holdings in Boston Scientific were worth $295,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of BSX. Precision Wealth Strategies LLC acquired a new position in Boston Scientific during the 4th quarter valued at approximately $956,000. Aveo Capital Partners LLC raised its stake in Boston Scientific by 1.3% in the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock worth $742,000 after acquiring an additional 171 shares during the last quarter. Private Advisor Group LLC raised its stake in Boston Scientific by 10.6% in the 4th quarter. Private Advisor Group LLC now owns 26,735 shares of the medical equipment provider’s stock worth $1,546,000 after acquiring an additional 2,572 shares during the last quarter. Wealthspire Advisors LLC lifted its position in Boston Scientific by 24.6% during the 4th quarter. Wealthspire Advisors LLC now owns 4,767 shares of the medical equipment provider’s stock worth $276,000 after acquiring an additional 942 shares during the period. Finally, Montag A & Associates Inc. grew its stake in Boston Scientific by 421.0% during the 4th quarter. Montag A & Associates Inc. now owns 14,587 shares of the medical equipment provider’s stock valued at $843,000 after purchasing an additional 11,787 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Argus lifted their target price on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. TD Cowen increased their price objective on shares of Boston Scientific from $77.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 target price on shares of Boston Scientific in a report on Thursday, July 25th. The Goldman Sachs Group started coverage on shares of Boston Scientific in a report on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Truist Financial lifted their price objective on Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $85.38.

Insider Activity

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares in the company, valued at $3,061,135.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 20,949 shares of company stock worth $1,627,877 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $81.64 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The stock has a market capitalization of $119.77 billion, a PE ratio of 68.61, a P/E/G ratio of 2.71 and a beta of 0.78. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $82.47. The company has a fifty day moving average of $77.40 and a two-hundred day moving average of $73.48.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The firm had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the prior year, the firm earned $0.53 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.